SCHEMBL31546341

SCHEMBL31546341

O=C(NCCCN1CCC(Cc2ccccn2)CC1)N1CCN(c2nc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ TP53 P04637 3/20 0.46
▸ HTT P42858 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TSHR P16473 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CHRM4 P08173 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SLC6A2 P23975 3/20 0.43
▸ SLC6A4 P31645 3/20 0.43
▸ GSK3B P49841 2/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ TUBB4A P04350 1/20 0.41
▸ TUBB P07437 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584882 0.92 LMNA (0.46) EPHX2ALDH1A1LMNATP53HTT
SCHEMBL30584895 0.90 LMNA (0.45) EPHX2ALDH1A1LMNATP53HTT
SCHEMBL31546447 0.90 CCR3 (0.46) EPHX2ALDH1A1LMNATP53HTT
SCHEMBL30584727 0.90 LMNA (0.47) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL31667543 0.90 LMNA (0.58) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584805 0.89 LMNA (0.48) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584775 0.89 LMNA (0.49) EPHX2ALDH1A1LMNATP53HTT
Formic Acid SCHEMBL31546410 0.88 LMNA (0.56) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL31667398 0.79 LMNA (0.55) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL31546418 0.79 LMNA (0.72) ALDH1A1LMNATP53HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP claimed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 EPHX2 4794/4885ALDH1A1 4471/4885LMNA 1344/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 EPHX2 4794/4885ALDH1A1 4471/4885LMNA 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback